Clinical Trials

Developing effective localized treatments to address unmet needs across a number of skin conditions

Multicenter, randomized double-blind, vehicle-controlled Phase 2a study for “Atopic Dermatitis”

STUDY IDENTIFIER

NCT05487963

Multicenter, randomized double-blind, vehicle-controlled Phase 2b study for “Atopic Dermatitis”

STUDY IDENTIFIER

NCT06810050

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis